It's a shame, that each and everyone has become too focused
It's a shame, that each and everyone has become too focused on Covid-19.
We we're doing great regarding HIV and cancer.
It looks like everything has been dropped for Covid-19.
Not filing BLA as promised is a huge mistake. Unneccessary as since january/february the filing has always been days away.
Now we've attracted mostly new investors that are in it for Covid-19.
I feel we're going to miss the boat there. Not because of the product, but because of we just don't have the resources BP has.
Doctors are too busy to pay attention to some doctor in NY or Florida having good results with Leronlimab.
They're going to chose/try what they do hear and that's just what BP promotes.
I feel we're wasting valuable time and money on something that will never be.
Not advocating to leave patients in the cold, but just don't put anymore effort in it. Don't use our scarse resources for a lost cause.
Just finish the BLA trial. Get Jonah Sacha's results published. Work on Prep. Basket trial? No use as long as we're in the CV shit. Vulnerable people avoid going to hospitals if they don't have to. Clinical trials means more hospital contacts. Thus, people avoid that.
5
1
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Fidelis Care Steps Up Workforce Engagement Fidelis Care's latest move introduces a fresh shot at tackling two birds with one stone—economic and health stability for Medicaid members. The Workforce Pathways to Health and Economic Mobility grants present up to $120,000 in support for New Yorkers, an attempt aimed squarely at reducing the vicious cycle that traps many in...
Continue Reading
Ever stood in a place where history feels so heavy you can almost touch it? That's Lazikou, a gorge in southern Gansu, where ninety years ago, young soldiers of China's Red Army faced a seemingly impassable barrier. Yet, they managed to climb, transform a military retreat into legend, and essentially shape the nation's path ahead. It's a feat that still sends ripples...
Continue Reading
Firehawk Defense Lands Major Funding Think about it—Firehawk Defense, a gutsy Dallas-based new-kid-on-the-block, just snagged a whopping $150 million in fresh funding. The news? Their valuation's now sitting pretty at $1.4 billion. Not peanuts, by any means. For a company in the artillery game, that's a blast of an announcement. They're predicting they'll become the big...
Continue Reading
Vertiv's Third Quarter Triumph Imagine a company blowing past expectations like a hot knife through butter—yeah, that's Vertiv for you in 2026. These guys didn’t just ride the wave; they created a tsunami in the digital infrastructure sector. Net sales ballooned by a staggering 61% compared to last year's same quarter, pulling in $4.313 billion. When you consider the...
Continue Reading
Amgen Prepares to Reveal Third Quarter 2026 Financials If there's one thing I've learned about investing, it's that the devil's in the details, and Amgen's (NASDAQ:AMGN) upcoming webcast for its third quarter 2026 financial results is exactly the kind of detail that sets market-watchers' hearts racing. Scheduled for November 3, just after the U.S. markets close, this is...
Continue Reading
Users Crown Data Integration Champions Right out of the gate, let's make one thing clear: when you're picking a data integration solution, you're essentially hitching your wagon to a vendor. This partnership, like any, can make or break your operations, and no one knows this better than the folks who've been through the trenches. Enter Infotech's 2026 Emotional Footprint...
Continue Reading
Navigating College Choices: More Than Just a Hunch When it comes to picking the right college, a lot of folks think it's like shooting in the dark—it's more than just a blind dart throw at a life map. According to a new report from the College Board, aligning with the right academic institution isn't merely a nice-to-have deal; it fundamentally shifts the odds in favor...
Continue Reading
Cracking the Mystery of Multilevel Locations Let me tell you, when lives hang in the balance, every second counts. We've all seen the chaos when first responders are trying to pinpoint someone's location inside a building with more floors than a loaf of bread. Enter GeoComm and Rypplzz, the new superheroes in this story. These two companies have realized the opportunity...
Continue Reading
Let's cut straight to the chase: the probiotics in animal feed market is steaming ahead, set to grow from a respectable $5.82 billion in 2026 to a hearty $8.76 billion by 2031. We're talking about a solid CAGR of 8.5% here. Now that's the kind of growth trajectory that gets even the most jaded traders sitting up and taking notice. Big Numbers in Livestock Nutrition...
Continue Reading
A Fresh Play: Swapping Old for New With a fresh brew in hand and the latest company maneuvers on the table, JELD-WEN's move to exchange its 4.875% Senior Notes due 2027 for new secured notes maturing in 2031 comes into focus. This ain't just some routine shuffling of papers. They're calling up eligible folks holding onto those old notes, saying, 'Why stick with the old...
Continue Reading
Top 5 Most Recently Viewed Articles
The AI Market Landscape in 2025 The artificial intelligence (AI) market, which has been largely dominated by Nvidia Corp. (NASDAQ: NVDA), appears to be undergoing significant changes as new players in the semiconductor industry are now outperforming the leader. This shift reflects a broader investor interest in various segments of the AI hardware stack, moving away from a...
Continue Reading
Strategic Leadership in Marine Cargo Underwriting HDI Global has announced a significant leadership change with the appointment of Hannah Brooke as the new Head of Marine Cargo Underwriting for the UK and Ireland. Starting from January 1, 2025, Brooke is set to enhance the company's Marine Cargo operations, focusing on a robust growth strategy. Background of Hannah Brooke...
Continue Reading
Altimmune's Upcoming Investor Conferences GAITHERSBURG, Md. — Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company known for its innovative peptide-based therapeutics targeting liver and cardiometabolic diseases, has exciting news. Members of Altimmune's management team will be attending two notable investor conferences where they will engage in discussions,...
Continue Reading
Celebrating the National Skilled Trade and Technology Week OTTAWA, Ontario - Skills/Compétences Canada (SCC) proudly honors the National Skilled Trade and Technology Week (NSTTW), which serves to enlighten students and educators about the vast career opportunities in skilled trades across Canada. Interactive Events Focused on Skills Development On this special occasion,...
Continue Reading
Key Insights into Voting Rights ICG Enterprise Trust plc aims to keep its shareholders informed about significant aspects of governance, including the vital area of voting rights. These rights play an essential role in corporate democracy, enabling shareholders to express their opinions on crucial company decisions. Current Voting Rights Overview As of the end of December...
Continue Reading